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In myeloma, data on immunophenotypic remission (IR) after an allograft are lacking. Our study 
compared the impact of IR to that of complete clinical remission (CR) in 66 consecutive patients, 
median age 54 years (35-66), transplanted between 2000 and 2011, and with at least a follow-up of 
3 months. Disease response was evaluated by serum/urine electrophoresis and bone marrow aspirate 
at scheduled time-points. Skeletal survey or MRI were performed yearly or as clinically indicated 
(overt relapse or complaints of bone pain). IR was defined as absence of monoclonal marrow 
plasma-cells detected by 4 or 6-colour staining flow cytometry using CD38, CD138, CD56, CD19, 
CD45, cyKappa, cyLambda. CCR was defined according to standard criteria. Conditioning regimen 
was non-myeloablative in 55 patients, reduced-intensity in 10 and myeloablative in 1. Donors were 
HLA identical siblings in 58 patients and unrelated in 8. Thirty-five/66 (53%) received an allograft 
up-front. In patients surviving at least 3 months, treatment related mortality was 10.6% at 3 years. 
After a median follow-up of 69 months (19-147), incidence of acute and chronic graft-versus-host 
disease was 45% and 49%, with no significant difference between responsive and refractory 
patients. At follow-up, 24/66 (36%) patients achieved CR and IR (CR/IR), 22/66 (33%) achieved IR 
but not CR because of persistence of the M-component (noCR/IR), and 20/66 (31%) did not 
achieve either CR or IR (noCR/noIR). Median overall (OS) and event-free survivals (EFS) were not 
reached and 59 months in the CR/IR group, 77 and 15 months in the noCR/IR, and 30 and 5 months 
in the noCR/noIR respectively (p<0.001 for both OS and EFS). Belonging to the CR/IR group was 
the only statistically significant predictor for prolonged OS and EFS (p<0.001). Of note, cumulative 
incidence of extramedullary disease at first relapse post-trasnsplant was 4.4% in the CR/IR, 31.8% 
in the noCR/IR and 15.0% in the noCR/noIR groups respectively (p<0.001). In conclusion, the 
achievement of IR showed a significant impact on clinical outcomes including patients who did  not 
clear the M-component. Discrepancies between IR and CR, and a higher incidence of 
extramedullary relapse in the noCR/IR group suggest that myeloma cells may escape immune 
control outside the bone marrow. In this group, positron emission tomography may be indicated to 
detect early relapse.     
 
 
 
